Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
$4.4MCash on Hand
3.6mo Cash Runway
Follow NIVF by emailGet an email when NIVF reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.
We send one confirmation email first. Only emails about NIVF, unsubscribe in one click. Privacy
📄 Latest SEC Filings in Plain English
Nov 17, 2026 ·
As of November 17, 2026, NewGenIvf had 2,790,883 Class A and 9,136 Class B ordinary shares outstanding, with 2,752,036 Class A shares held by non-affiliates. Convertible notes total US$2,044,373, of which only US$323,812 is currently eligible for conversion. Form 6-K · SEC filing
Nov 16, 2026 ·
NewGenIvf reported that IVF revenue was broadly flat for the six months ended June 30, 2026. Cash was about US$1.02 million, and a US$4.71 million land deposit for Ras Al Khaimah remains without a signed purchase agreement. A non-binding Hainan Provincial Cancer Hospital collaboration for NX One was also announced. Form 6-K · SEC filing · Press release
Oct 27, 2026 ·
Financing NewGenIvf filed a shelf registration for up to US$100 million of securities, including Class A ordinary shares, preferred shares, warrants, debt securities, subscription rights and units, to be offered from time to time. Form F-3 · SEC filing
Oct 21, 2026 ·
Listing NewGenIvf approved a 1-for-8 reverse stock split, effective October 23, 2026, with trading under the same NIVF symbol and a new CUSIP G0544E162. Outstanding Class A shares are expected to fall from about 9,821,197 to about 1,227,650, and no shareholder vote is required. Form 6-K · SEC filing
Oct 7, 2026 ·
Earnings NewGenIvf reported unaudited results for the six months ended June 30, 2026, with revenues of $1,924,881 (down from $2,019,628), a net loss attributable to shareholders of $8,035,306 (versus net income of $724,975), and a $6,881,250 Repurchase Forbearance liability. Four reverse share splits were effected in 2026. Form 6-K · SEC filing · Press release
Oct 7, 2026 ·
Listing Board approved a 1-for-4 reverse stock split of all issued and unissued shares, effective October 12, 2026, with trading continuing as NIVF under new CUSIP G0544E600. Outstanding Class A shares expected to fall from about 35,688,329 to about 8,922,083. No shareholder vote required. Form 6-K · SEC filing
Oct 5, 2026 ·
Financing As of October 1, 2026, NewGenIVF had 27,287,002 class A ordinary shares outstanding, reflecting issuances from a best efforts offering announced September 30, 2026, convertible note conversions, and its equity line of credit. Form 6-K · SEC filing
Sep 30, 2026 ·
Financing Prices a best-efforts offering of 125,000 Class A shares and 17,732,143 pre-funded warrants at $0.07 per share, a discount of about 79.70% to the $0.3448 last sale price. Aegis Capital Corp. is placement agent for an 8.0% fee, and three holders may resell up to 4,364,044 shares from convertible notes. Form 424B4 · SEC filing
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
💰 Cash Runway & Dilution Risk
NIVF holds $4.4M in cash and short-term investments and burns about $3.7M/quarter from operations,
an estimated runway of 3.6 months at that rate (BioRadar estimate, not company guidance).
Dilution pressure:40 · Elevated
Cash runway 4 months +40
Shelf registration (F-3, Oct 2026) +10
Raised after last reported balance sheet (Aug 2026) -10
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for NIVF and every other ticker you follow. Card required, cancel anytime.
Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.